RAPAMUNE*30CPR RIV 1MG ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
67多発性嚢胞腎1

67. 多発性嚢胞腎


臨床試験数 : 221 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-003427-37-IT
(EUCTR)
05/02/200727/12/2006Sirolimus treatment in patients with autosomal dominant polycystic kidney disease renal efficacy and safety - NDSirolimus treatment in patients with autosomal dominant polycystic kidney disease renal efficacy and safety - ND Autosomal-Dominant Polycystic Kidney Disease ADPKD
MedDRA version: 9.1;Level: LLT;Classification code 10010428;Term: Congenital cystic kidney disease
Trade Name: RAPAMUNE*30CPR RIV 1MG
INN or Proposed INN: Sirolimus
Trade Name: RAPAMUNE*30CPR RIV 2MG
INN or Proposed INN: Sirolimus
IST. DI RICERCHE FARMACOLOG. M. NEGRINULLNot Recruiting Female: yes
Male: yes
16 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noItaly